69 Biotech Startups in UK to Watch in 2024
How do we build this list?
Tracking:
Last update to the database: March 25, 2024. See changelog.
Join 23,000+ founders, operators and investors.
Seedtable Score Learn how we calculate it here
We use raw data and human intuition to understand if a company is likely to outsource services like Hiring, Design, Development, etc.
company | score | funding | investors | employees | industries | biz model | city | contact |
---|---|---|---|---|---|---|---|---|
Portfolio of pharmaceutical research and discovery. |
$33M · Series C | Patient Square Capital, Rock Springs Capital, M&G Investments | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@apollotherapeutics.com | ||
Biomedical research discovery tool. |
$60M · Series B | Index Ventures, ICONIQ Growth, Pentech Ventures | 51 to 100 | Health Tech, AI, Biotech, Pharma | B2B, SaaS | London, UK | •••••••••••@causaly.com | |
AI vaccine algorithm developer. |
$11M · Series A | Hoxton Ventures, Merck Global Health Innovation Fund, Cherry Ventures | 1 to 10 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@baseimmune.co.uk | |
Preclinical stage treatment for geographic atrophy. |
$78M · Series A | Forbion Capital Partners, Gimv | 1 to 10 | Biotech | London, UK | •••••••••••@complementtx.com | ||
Oophthalmic gene therapy company to treat blinding retinal illnesses. |
$120M · Series A | Syncona Partners LLP | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@beacontx.com | ||
AI platform to map the human immune system. |
$14M · Series A | Molten Ventures, Life Extension Ventures | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@imubiosciences.com | ||
Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits. |
$28M · Series B | Future Planet Capital | 11 to 50 | Agritech, Biotech, Deep Tech, Manufacturing | B2B | London, UK | •••••••••••@tropicbioscience.com | |
Fully-automated cell manufacturing. |
$19M · Series A | Buckley Ventures, Wing Venture Capital, IQ Capital Partners | 11 to 50 | Biotech, Machine Learning | B2B | London, UK | •••••••••••@mytos.bio | |
Developer of non-biological affinity reagents to accelerate the production of cell and gene therapies. |
$8M · Series A | Mercia Asset Management | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@mipdiscovery.com | ||
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. |
$30M · Series A | Kindred Capital, Octopus Ventures, Amadeus Capital | 1 to 10 | Health Tech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@oribiotech.com | |
Discovery and development platform of superior microbial bioproducts. |
$6M · Series A | Pymwymic, Clean Growth Fund | 1 to 10 | Biotech | London, UK | •••••••••••@fungialert.com | ||
Quell Therapeutics is a cell therapy company |
$45M · Series A | AlbionVC, Point72 Ventures | 101 to 250 | Health Tech, Edtech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@quell-tx.com | |
Neuroscience-driven AI platform. |
$2M · Seed | Rockmount Capital, Moonfire Ventures, UCL Technology Fund | 11 to 50 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@stanhopeai.com | |
ReViral is a biotechnology company that develops and offers antiviral therapies for patients. |
$44M · Series C | Novo A/S, Andera Partners | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@reviral.co.uk | |
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins. |
$50M · Series A | General Catalyst, Khosla Ventures | 1 to 10 | Health Tech, AI, Biotech, Data and Analytics | B2B | London, UK | •••••••••••@charmtx.com | |
Gene silencing platform for the creation of programmable, allogeneic cell therapies. |
$16M · Seed | Mercia Asset Management, Calculus Capital, UK Innovation & Science Seed Fund | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@laverocktx.com | ||
Clinical trials platform. |
$18M · Series A | Valar Ventures, Creandum, Seedcamp | 11 to 50 | Health Tech, Biotech | B2B, SaaS | London, UK | •••••••••••@lindushealth.com | |
LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. |
$25M | Kindred Capital, Atomico | 51 to 100 | Health Tech, AI, Biotech, Deep Tech, Machine Learning, Robotics, Manufacturing | B2B | London, UK | •••••••••••@labgeni.us | |
Immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. |
$17M · Seed | AlbionVC, Boxer Capital, Syncona Partners LLP | 101 to 250 | Health Tech, Biotech | B2B | London, UK | •••••••••••@achillestx.com | |
Clinical-stage research for alzheimer’s disease. |
$58M · Series A | EQT Partners, UCL Technology Fund, Brandon Capital | 1 to 10 | Health Tech, Biotech | Reading, UK | •••••••••••@astronautx.bio | ||
Short-duration psychedelic medicines developer for neuropsychiatric conditions. |
$40M · Series B | ATAI Life Sciences, Leafy Tunnel | 1 to 10 | Biotech, Pharma | B2C | Oxford, UK | •••••••••••@beckleypsytech.com | |
Platform to automate the clinical studies process. |
$12M · Series A | Playfair, AlbionVC, Delin Ventures | 11 to 50 | Health Tech, Biotech | B2B | London, UK | •••••••••••@umed.io | |
Developer of drugs to treat respiratory diseases. |
$2M · Series A | Forbion Capital Partners, Epidarex Capital, Imperial Innovations | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@enterprisetherapeutics.com | ||
Precision software for eye surgery. |
$8M · Seed | Redalpine | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@hypervisionsurgical.com | ||
Immuno-oncology company treats cancer with antibodies. |
$2M · Series A | AlbionVC, Epidarex Capital, Novartis Venture Fund | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing, Genetics | B2B | London, UK | •••••••••••@epsilogen.com | |
Precision therapeutics discovery platform. |
$6M · Seed | Hoxton Ventures | 11 to 50 | Biotech | B2B | London, UK | •••••••••••@multiomic.uk | |
Cancer treatment predictor software. |
$14M · Series A | Hoxton Ventures, Octopus Ventures, Fly Ventures | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@pearbio.com | |
Patent-protected anti-inflammatory painkiller. |
$6M · Series A | ITV AdVentures | 1 to 10 | Biotech, Pharma | B2C | London, UK | •••••••••••@flarin.co.uk | |
User-owned genomics database platform. |
$20M · Series A | GEM Digital | 1 to 10 | Health Tech, Biotech | B2C | London, UK | •••••••••••@genomes.io | |
Developer of therapeutics for chronic autoimmune and inflammatory diseases. |
$38M · Series A | Sofinnova Partners, GSK, SV Health Investors | 11 to 50 | Health Tech, Biotech | Oxford, UK | •••••••••••@sitryx.com | ||
Biomedical CloudOS data platform. |
$120k · Seed | Eurazeo, Connect Ventures, Techstars | 51 to 100 | Health Tech, Biotech, Data and Analytics, Business Intelligence | B2B, SaaS | London, UK | •••••••••••@lifebit.ai | |
Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies. |
$10M | Y Combinator, Pi Campus | 11 to 50 | Health Tech, Biotech, Robotics, Manufacturing, Business Intelligence | B2B | London, UK | •••••••••••@sixfold.bio | |
Building the future of food, starting with dairy. |
$2M · Seed | Entrepreneur First, Vorwerk Ventures, Redalpine | 1 to 10 | Agritech, Foodtech, Biotech, Manufacturing | B2B, B2C | London, UK | •••••••••••@betterdairy.co.uk | |
Based in London, UK, Hoxton Farms is growing cultivated fat as an ingredient for the meat alternatives industry. |
$3M · Seed | BACKED VC, CPT Capital | 11 to 50 | Foodtech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@hoxtonfarms.com | |
Pathfinder is developing a novel catheter based system that provides a better way for patients to receive haemodialysis for kidney failure. |
$11M · Series A | Business Growth Fund, Parkwalk Advisors, Deepbridge Capital | 1 to 10 | Health Tech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@pathfindermed.com | |
Daye is a gynecological health company that creates products and services for vaginal treatment. |
$5M · Seed | Index Ventures, Khosla Ventures, Kindred Capital | 11 to 50 | Health Tech, Biotech, Manufacturing, Ecommerce, Cannabis | B2C | London, UK | •••••••••••@yourdaye.com | |
3D human lung model developer. |
$2M · Seed | Pioneer Group, Mercia Asset Management, Midlands Engine Investment Fund | 11 to 50 | Biotech, Deep Tech | London, UK | •••••••••••@immuone.com | ||
Protein discovery research and manufacturing. |
$19M · Series A | SYSTEMIQ | 11 to 50 | Biotech, Deep Tech | London, UK | •••••••••••@basecamp-research.com | ||
Developer of cutting-edge DNA techniques to monitor biodiversity. |
$3M · Seed | SYSTEMIQ, BNP Paribas, Green Angel Ventures | 11 to 50 | Biotech | London, UK | •••••••••••@naturemetrics.co.uk | ||
Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors. |
$6M · Seed | Sofinnova Partners | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@myricxpharma.com | |
OpenCell builds biotech labs in shipping containers with the aim of making biotechnology accessible and affordable. |
$8M | Seventure Partners | 1 to 10 | Fintech, Biotech, Proptech & Real Estate, Manufacturing | B2B, SaaS | London, UK | •••••••••••@opencell.bio | |
We are a translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered proteins. |
$2M | Hoxton Ventures, Bessemer Venture Partners | 11 to 50 | Health Tech, Biotech, Pharma, Manufacturing | B2B | London, UK | •••••••••••@peptone.io | |
Lab-quality diagnostics for anyone, anywhere, at any time. |
$85M | Oxford Science Enterprises | 51 to 100 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Oxford, UK | •••••••••••@oslerdiagnostics.com | |
MiroBio is Harnessing the natural control mechanisms of the immune system. |
$97M · Series B | Medicxi, Oxford Science Enterprises | 1 to 10 | Health Tech, Biotech, Deep Tech | B2B | Oxford, UK | •••••••••••@mirobio.com | |
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases. |
$70M | Sofinnova Partners, Novo A/S, Forbion Capital Partners | 251 to 500 | Health Tech, Biotech, Pharma, Genetics | B2B | Manchester, UK | •••••••••••@f2g.com | |
ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers. |
$75M · Series B | Axon Ventures, Oxford Science Enterprises | 51 to 100 | Health Tech, Biotech, Deep Tech, Robotics, Manufacturing, Developer Tools | B2B | Oxford, UK | •••••••••••@oni.bio | |
Drug delivery platform. |
$24M · Series A | 4BIO Capital, UCB Ventures, Business Growth Fund | 1 to 10 | Health Tech, Biotech | Cambridge, UK | •••••••••••@vianautis.com | ||
Oncology treatment plalform. |
$35M · Series B | Kurma Partners, Seroba Life Sciences, Enterprise Ireland | 1 to 10 | Biotech | Cork, UK | •••••••••••@shorlapharma.com | ||
AI platform to advance precision medicine clinical trials. |
$11M · Series A | Seedcamp, Plural, MMC Ventures | 11 to 50 | Health Tech, Biotech | B2B, SaaS | Cambridge, UK | •••••••••••@sanogenetics.com | |
Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins. |
$275M | Wellington Management | 251 to 500 | Health Tech, Biotech, Pharma, Robotics, Manufacturing, Genetics | B2B | Oxford, UK | •••••••••••@nanoporetech.com | |
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases. |
$56M · Series B | Balderton Capital, Atomico, btov Partners | 51 to 100 | Health Tech, AI, Biotech, Pharma, Data and Analytics, Business Intelligence | B2B, SaaS | Cambridge, UK | •••••••••••@healx.io | |
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. |
$66M | Seventure Partners, Cambridge Innovation Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Manufacturing | B2B | Cambridge, UK | •••••••••••@microbiotica.com | |
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. |
N/A | Forbion Capital Partners | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@pheontx.com | |
Developer of innovative treatment for muscle wasting disorders. |
$1M · Seed | Mankind Pharma | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@actimedtherapeutics.com | ||
AI-powered drug testing platform. |
$1M · Pre Seed | Seedcamp, Episode 1 | 1 to 10 | AI, Biotech | London, UK | •••••••••••@sablebio.com | ||
Cell-free chemical manufacturer to produce bio-based alternatives |
$3M · Seed | Hoxton Ventures, Atomico, BACKED VC | 11 to 50 | Biotech | B2B | London, UK | •••••••••••@fabricnano.com | |
Epoch develops natural solutions to unnatural problems. First up: enzymes that transform plastics into circular chemicals. |
$3M · Pre Seed | Lowercarbon Capital, BoxGroup, Amadeus Capital | 11 to 50 | Biotech, Manufacturing | B2B | London, UK | •••••••••••@epochbiodesign.com | |
Digital-twin simulator. |
$3M · Pre Seed | Crane Venture Partners | 1 to 10 | Biotech, Supply Chain & Logistics | B2B | London, UK | •••••••••••@quaisr.io | |
Computer simulation to understand drug-bacteria interactions. |
$5M · Seed | Hoxton Ventures, Sofinnova Partners | 1 to 10 | Biotech | London, UK | •••••••••••@biocortex.co.uk | ||
Quantum simulation platform for drug discovery. |
$2M · Seed | Ascension Ventures, ACF Investors | 1 to 10 | Health Tech, Biotech | B2B, SaaS | London, UK | •••••••••••@kuano.ai | |
At-home fertility treatment. |
$3M · Seed | Octopus Ventures, Calm/Storm Ventures, QVentures | 1 to 10 | Health Tech, Biotech | B2C | London, UK | •••••••••••@beafertility.com | |
Gene and cell therapy manufacturing. |
$65M · Series A | 11 to 50 | Biotech | London, UK | •••••••••••@ascend-gctx.com | |||
Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. |
$42M · Series B | Future Planet Capital, Amadeus Capital, Verve Ventures | 11 to 50 | Biotech, Deep Tech, Manufacturing | B2B | Cambridge, UK | •••••••••••@nuclera.com | |
AI-powered live stem cells behaviour tracking platform. |
$9M · Seed | Air Street Capital, Octopus Ventures, Horizons Ventures | 1 to 10 | AI, Biotech | Bristol, UK | •••••••••••@cellvoyant.com | ||
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. |
$41M · Series A | Metaplanet Holdings, BlueYard Capital | 101 to 250 | Health Tech, Biotech, Deep Tech, Business Intelligence | B2B | Cambridge, UK | •••••••••••@bit.bio | |
Developer of antibodies to treat diabetic peripheral arterial disease. |
$9M · Seed | Broadview Ventures, MEIF Proof-of-Concept & Early Stage Fund, Mercia Asset Management | 1 to 10 | Health Tech, Biotech | Nottingham, UK | •••••••••••@isomab.bio | ||
Mogrify® will transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies. |
$10M · Series A | Astellas Venture Management, Ahren Innovation Capital, Parkwalk Advisors | 101 to 250 | Health Tech, Biotech, Deep Tech | B2B | Cambridge, UK | •••••••••••@mogrify.co.uk | |
Anti-cancer drug developer. |
$28M · Series A | Syncona Partners LLP, Cambridge Innovation Capital | 101 to 250 | Biotech | Cambridge, UK | •••••••••••@mosaic-tx.com | ||
Foodsteps is a london-based startup that has developed a platform to help the food sector reduce its carbon footprint. |
$4M | Octopus Ventures, Ascension Ventures, Metaplanet Holdings | 11 to 50 | Climate Tech & Green Tech, Health Tech, Agritech, Foodtech, Biotech, Deep Tech, Energy & Nuclear, Business Intelligence | B2B, SaaS | London, UK | •••••••••••@foodsteps.earth |
Sign up to access our full database
Enter your email and get access to 17,000+ technology companies you can partner with.